
Johnson & Johnson
OrganizationHeard in 185 episodes across 50 shows since Sep 2025
Johnson & Johnson is an American multinational healthcare company focused on pharmaceutical medicines and medical technologies, including medical devices. The podcast references primarily concern the publicly traded parent company, its pharmaceutical and medical-device businesses, earnings and stock performance, and its former consumer-health portfolio, which was separated into Kenvue in 2023 rather than remaining part of J&J.
Episodes
This week
Expert statements
Share of the conversation
Mentions of Johnson & Johnson per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Oct 13 | 0.17‰ | 10 |
| Oct 14 | 0.17‰ | 2 |
| Oct 15 | 0.18‰ | 2 |
| Oct 16 | 0.19‰ | 4 |
| Oct 19 | 0.19‰ | 4 |
| Oct 20 | 0.12‰ | 2 |
| Oct 21 | 0.15‰ | 6 |
| Oct 22 | 0.15‰ | 2 |
| Oct 26 | 0.11‰ | 3 |
| Oct 27 | 0.12‰ | 3 |
| Oct 28 | 0.07‰ | 1 |
| Oct 29 | 0.08‰ | 2 |
| Oct 30 | 0.09‰ | 2 |
| Oct 31 | 0.10‰ | 1 |
| Nov 2 | 0.08‰ | 1 |
| Nov 3 | 0.08‰ | 2 |
| Nov 4 | 0.07‰ | 1 |
| Nov 5 | 0.08‰ | 3 |
| Nov 6 | 0.08‰ | 2 |
| Nov 9 | 0.07‰ | 1 |
| Nov 10 | 0.06‰ | 1 |
| Nov 12 | 0.07‰ | 4 |
| Nov 13 | 0.06‰ | 1 |
| Nov 14 | 0.08‰ | 3 |
| Nov 16 | 0.09‰ | 3 |
| Nov 17 | 0.11‰ | 3 |
| Nov 18 | 0.13‰ | 2 |
| Nov 19 | 0.10‰ | 1 |
| Nov 20 | 0.11‰ | 2 |
| Nov 22 | 0.10‰ | 1 |
Email alert
Email me when Johnson & Johnson comes up on a podcast
One email a week at most, with the new episodes that mention Johnson & Johnson. Free, no account needed, unsubscribe in one click.
What experts have said about Johnson & Johnson
68 statements · 63 positive · 2 negative · 1 mixed · 2 neutral
The Allen transaction includes more than $1.1 billion in regulatory and commercial milestones.
“There's another 1.1 or a little more. in regulatory and commercial milestones.”
Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton OddsListen at 2:18
Johnson & Johnson is buying All In Biosciences for over $2 billion.
“the drugmaker is buying iDisease Biotech Company All In Biosciences for over $2 billion.”
Open the episode · NVIDIA's China Loophole & The Aviation Blame GameListen at 17:04
Johnson & Johnson will likely continue growth and dividend payments.
“I think you're gonna likely continue to see some growth, continue to see that dividend.”
Open the episode · Fast Money: FAA Ground Stop, Anthropic IPO and AI Market Rotation 11/13/26Listen at 37:29
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
185 episodes featuring Johnson & Johnson, newest first
- Nov 22, 2026
Compass Pathways bets on supervised psilocybin therapyMotley Fool Hidden Gems InvestingNov 22, 2026 - Nov 20, 2026
Nvidia sell-off exposes wider cracks in the AI tradeCNBC's "Fast Money"Nov 20, 2026 - Nov 20, 2026
AI valuations meet public-market realityThe Compound and FriendsNov 20, 2026 - Nov 19, 2026
Anthropic’s debut tests AI valuations as markets retreatCNBC's "Fast Money"Nov 19, 2026 - Nov 18, 2026
Target’s Pokémon surge tests retail momentumBrew MarketsNov 18, 2026 - Nov 18, 2026
AI’s infrastructure boom collides with human agencyTBPNNov 18, 2026